Dr. Rotow received her M.D. from the UCLA David Geffen School of Medicine. She completed her residency training in Internal Medicine at the Massachusetts General Hospital and her fellowship training in Hematology/Oncology at the University of California, San Francisco. As a thoracic oncologist at the Dana-Farber Cancer Institute her research interests include the development of targeted therapies and immunotherapies for the treatment of oncogene-driven lung cancer.

Christian Rolfo, MD, PhD, MBA, Dr.hc. is professor in the Division of Hematology-Oncology at University of Maryland School of Medicinethe, Director of the Thoracic Medical Oncology and the Early Clinical Trials at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC). He specializes in thoracic oncology, drug development and translational oncology. Dr. Rolfo received his medical degree from the National University of Córdoba, Argentina in 1996, and University of Catania, Iatly in 2003. He completed his fellowship in Medical Oncology at University of Milan, Italy. He has earned certifications from the European Oncology Board and the Spanish and Belgian Board and spent an internship at MD Anderson Cancer Center in Houston. From 2012 to March 2018, Dr. Rolfo was the Director of Phase I - Early Clinical Trials Unit and Director of the Clinical Trials Management Program. In addition senior staff for the Thoracic Oncology Cluster at the Antwerp University Hospital in Belgium. In addition of Professor of the same University. Dr. Rolfo actively works on drug development and resistance in lung cancer and mesothelioma treatment. His focus of research are liquid biopsies (exosomes and ctDNA) and molecular profiling, he is involved in druggable biomarkers research and immunotherapy in thoracic cancer. Dr. Rolfo is the Deputy Chair of the Educational Committee of the International Association for the Study of Lung Cancer (IASLC), Vice President of The International Society of Liquid Biopsy (ISLB),Member of the Scientific Committee of the European School of Oncology (ESO). He served as Membership Committee of European Society of MedicaOncology (ESMO). He is a member of the American Society of Clinical Oncology (ASCO) the American Association of Cancer Research (AACR) and other societies. His work has been published in “New England Journal of Medicine,” “Lancet Oncology,” “Nature Nanotechnology,” "Cancer Discovery" “Journal of Thoracic Oncology” "Nature Rev Clin Oncology" among other journals. Read Dr. Rolfo's publications on PubMed. Speaking engagements include global forums on lung cancer and drug development.

Dr. Estelamari Rodriguez is Associate Director of Community Outreach and member of the Lung Cancer Site Disease Group of the NCI-designated Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine.  She has a special interest in the early detection of lung cancer and early phase clinical trials. She earned her medical degree from State University of New York (SUNY) Downstate College of Medicine. She completed her internal medicine residency at Columbia University’s New York-Presbyterian Hospital, and her medical oncology fellowship at the University of Pennsylvania. Dr. Rodriguez also has a master’s degree in Public Health from the Universidad Autonoma de Madrid, Spain

Jacqulyne Robichaux, Ph.D is a research assistant professor in the department of Thoracic/Head and Neck Medical Oncology at MD Anderson Cancer Center, and she is currently an AACR-FDA Oncology Educational Fellow. She obtained her Bachelor of Science in Chemistry from Nicholls State University summa cum laude, and attained her Ph.D. in Biomedical Sciences from the Medical University of South Carolina, where she was a recipient of the distinguished graduate student award. Dr. Robichaux completed her postdoctoral training at MD Anderson in the lab of John Heymach where she identified poziotinib as an effective inhibitor of EGFR and HER2 exon 20 insertion mutations in preclinical studies. Currently, her research is focused on identifying targeted therapies for other atypical EGFR and HER2 mutations through the analysis of the structure-function relationship between inhibitor and receptor. In addition, she has ongoing research to understand mechanisms of resistance and regulation of EGFR/HER2 signaling in response to target therapies in NSCLC.

Medical oncologist with research focus in lung cancer immunotherapy mechanisms of sensitivity and resistance

Jonathan W. Riess, M.D., M.S. Dr. Riess is an Associate Professor of Medicine in the Division of Hematology-Oncology at UC Davis Comprehensive Cancer Center (UCDCCC). He is aninvestigator focusing on clinical and translational research in lung cancer - particularly precision therapeutics and immunotherapy.

Dr. Gregory Riely is a medical oncologist in the Thoracic Oncology Service at Memorial Sloan Kettering Cancer Center and the Weill Cornell Medical College. He is Vice Chair, Clinical Research in the Department of Medicine at Memorial Sloan Kettering. His conducts clinical research to better understand non-small cell lung cancer and develop new treatments. Dr. Riely received his BA from The Johns Hopkins University, and his PhD and MD degrees from Case Western Reserve University. He completed fellowship training in Medical Oncology at Memorial Sloan Kettering Cancer.

Joshua Reuss is a thoracic medical oncologist at Georgetown Lombardi Comprehensive Cancer Center and Assistant Professor of Medicine at Georgetown University School of Medicine. He has a particular research interest in early phase translational immunotherapy clinical trials in non-small cell lung cancer and mesothelioma with a focus on immunotherapy-refractory and resectable disease populations.

Karen L. Reckamp, MD, MS is Professor in Medicine, Director of the Division of Medical Oncology at Cedars-Sinai Medical Center. She received a master’s degree in Clinical Investigation from the department of Biomathematics at UCLA. Dr. Reckamp also serves as the Associate Director of Clinical Research for the Samuel Oschin Comprehensive Cancer Institute (SOCCI). She obtained my medical degree at the University of Chicago, Pritzker School of Medicine in 1998 with AOA distinction, and trained in Internal Medicine at Washington University’s Barnes-Jewish Hospital.  Dr. Reckamp completed fellowship training in Hematology/Oncology at the David Geffen School of Medicine, UCLA in June 2004, and completed a Master of Science degree in Clinical Research. She leads multiple phase I, II and III studies funded by the NCI, internal funds and industry.  Dr. Reckamp is a member of ASCO, AACR, International Association for the Study of Lung Cancer, and SWOG. She participated in the ASCO Leadership Development Program and led the Scientific Committee for metastatic lung cancer for the ASCO annual meeting. Dr. Reckamp has been the past recipient of many honors including American Lung Association, Lung Force Honoree in 2018. She has also authored or co-authored many manuscripts in the field of Thoracic Oncology. She has been selected to the Association of American Cancer Institutes Physician Clinical Leadership Initiative Steering Committee for 2021.

My research interest is translational clinical trials with a focus on immune therapy in thoracic oncology. I am presently a cadre committee member of the Alliance respiratory committee. I am the principal investigator for two successfully completed Duke Cancer Institute investigator initiated studies of neoadjuvant immune therapy in early stage non-small cell lung cancer.